<sup>EDITION</sup> ■ **HIV PERSISTENCE DURING THERAPY**<sup>™</sup> Reservoirs & Eradication Strategies Workshop

DECEMBER 13-16, 2022 www.hiv-persistence.com MIAMI USA

CLONALLY EXPANDED HIV-1 PROVIRUSES WITH 5'-LEADER DEFECTS CAN GIVE RISE TO NONSUPPRESSIBLE RESIDUAL VIREMIA AND COMPLICATE ART MANAGEMENT


> Francesco R. Simonetti, MD PhD Assistant Professor Johns Hopkins University



HAVE NO CONFLICTS OF INTEREST

www.hiv-persistence.com

# Some people on ART experience nonsuppressible residual viremia (NSV)




If residual viremia is a reflection of reservoir persistence (always present), why only some people experience NSV (rare)?

## **Participant Characteristics**

Characteristics	P1	P2	P3	P4	Median <sup>d</sup>
Sex	Male	Male	Female	Male	
Age (y)	63	60	58	60	60
Race	African American	Caucasian/White	African American	Caucasian/White	
Years since diagnosis	30	31	15	32	31
Years on ART	7.8	26.4	14.5	27	20
CD4 <sup>+</sup> T cell count nadir (cells/mm <sup>3</sup> )	454	197	221	na	
CD4 <sup>+</sup> T cell count, last (cells/mm <sup>3</sup> )	828	793	803	610	798
HIV-1 RNA, setpoint (copies/mL)	8771	na <sup>c</sup>	141667	na	
HIV-1 RNA, last (copies/mL) <sup>a</sup>	58	20	167	3400	<mark>11</mark> 3
Years with detectable viremia	5	11	5	5	5
ART regimen, last <sup>b</sup>	TAF,FTC,BIC	TAF,FTC,BIC,FTR	TAF,FTC,BIC	TAF, FTC, BIC, DOR, MVC	
Infectious units per million (QVOA)	<0.06	15 (10-21)	na	na	
Intact proviruses/10 <sup>6</sup> CD4 <sup>+</sup> T cells (IPDA)	3.5	311	161	58	110
HLA-B	53:01, 57:03	44:02	44:03	44:03, 57:02	


**Supplementary Table S1. Participant characteristics.** a, measured with limit of detection of 20 copies/mL; b, TAF tenofovir alafenamide fumarate, FTC emtricitabine, BIC bictegravir, FTR fostemsavir, DOR doravirine, MVC maraviroc; c, not available. d, median values were calculated when available for all 4 participants.

## NSV is caused by a single, rare, drug-sensitive variant





HIV PERSISTENCE DURING THERAPY Beservoirs & Eradication 🔘 DECEMBER 13-16, 2022 Mismi USA


### >10<sup>3</sup> copies/mL of HIV RNA caused by a single drug-sensitive variant





HIV PERSISTENCE DURING THERAPY Reservoirs & Eradication 🛞 DECEMBER 13-16, 2022 Miami USA













### 5'-L deletions only partially affect dimerization and Gag binding properties




HIV PERSISTENCE DURING THERAPY Reservoirs & Eradication O DECEMBER 13-16, 2022 Mismi USA

5'-L defective proviruses are inducible ex vivo upon T cell activation




HIV PERSISTENCE DURING THERAPY" Reservoirs & Eradication 🛞 DECEMBER 13-16, 2022 MFLAMMUSA


## 5'-L defective proviruses are inducible ex vivo upon T cell activation



### 5'-L defects result in non-infectious virus with low Envelope expression




## Proviruses cause of NSV are integrated into genes with variable expression in CD4<sup>+</sup> T cells, all in opposite orientation




HIV PERSISTENCE DURING THERAPY Reservoirs & Eradication 🔘 DECEMBER 13-16, 2022 Miami USA


### Clones expanded around onset of NSV and are stable over time



MINING THERAPY Beservoirs & Eradication Strategies Workshop Www.hiv-persistence.com

# Clones cause of NSV are siloed in Effector Memory cells







#### COMMUNITY SUMMARY

Key question What causes viremia that cannot be fully suppressed by ART?

**Key finding** Proviruses with <u>small defects in the 5'-Leader region</u> can also cause detectable viremia, up to thousands of copies per ml, complicating ART management.

This type of defects result in **non-infectious virus**, in part due to low expression of the Envelope.

These proviruses are found in <u>expanded CD4 T cell clones</u> that are stable over time thanks to frequent cell division.

**Next steps** How common is this phenomenon? What drives the constant virus production from specific infected cells cause of residual viremia? How can we get rid of them?

www.hiv-persistence.com

# Thank you All !!!

atric Adolescent Virus Elim

#### <u>Filippo Dragoni</u> Angelica Camilo Contreras

#### Siliciano Lab

Robert F. Siliciano Janet D. Siliciano Jennifer A. White Jiayi Duan Fengting Wu Milica Moskovljevic Joseph Varriale Jun Lai Subul Beg

#### **Retrovirus Lab**

Joe Mankowski Janice Clements Rebecca Veenhuis

#### **Computational Medicine**

Alison L. Hill Andrei Gheorghe

### BSPH Sorting Core Hao Zhang

Joseph B. Margolick

#### JHU/Bartlett

Joel Blankson Benjamin Larman Christopher Hoffmann Jerald Cherian Natasha Chida Joyce Jones Christin Kilcrease Patricia Barditch-Crovo

UMBC <u>Michael F. Summers</u> Saif Yasin

#### Montreal

Sebastien Poulin Frederic Chano Cecile Tremblay

# **Study Participants**



**BEAT-HIV** 


PERSISTENCE DURING THERAPY

fsimonetti@jhmi.edu

@SimonettiFR


DECEMBER 13-16, 2022

# Proviruses cause of NSV may elude CTL and antibody immune pressure




### Proviruses cause of NSV may elude CTL and antibody immune pressure

С




However, given the small number of virus-producing cells required to cause NSV at any given time, immune escape may not be necessary if proliferation outpaces immune clearance.

## Defects in the 5' Leader involve the major splicing donor site




### Small 5' leader deletions lead to noninfectious viral particles




PROVERSISTENCE DURING THERAPY Reservoirs & Eradication C December 13-16, 2022 Missistence.com Missistence.com Missistence.com

# 293 cells transfected with 5'L defective vector produce virions



NL4-3 d22



24

# *In Memoriam* of Giulio Maria Corbelli





BITCH PERSISTENCE DURING THERAPY Beservoirs & Eradication O DECEMBER 13-16, 2022 MIAMI USA